A New Prognostic Staging System for Hepatocellular Carcinoma: Value of the Biomarker Combined Japan Integrated Staging Score
Satoshi Kitai(Kindai University), Takashi Matsunaga(Osaka International Cancer Institute), Masatoshi Kudo(Kindai University), Shunsuke Takahashi(Kanagawa Dental University), Toshihito Seki(Kansai Medical University), Yasunori Minami, Yutaka Asakuma, Kazuomi Ueshima(Kindai University), Yo Sasaki(SHOWA Medical University), Tatsuo Inoue, Emi Ishikawa, Seiji Haji(Kindai University), Hiroshi Kasugai(Osaka International Cancer Institute), Yukio Osaki(Osaka Red Cross Hospital), Satoru Hagiwara(Kindai University Hospital), Hiroko Oka(Osaka City General Hospital), Hobyung Chung(Kindai University)
Cited by 42
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
|Science|2004|1.1k